DSDaniel Steiner

Daniel Steiner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel Steiner has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Cihan Ay

    Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

    4 shared publications
  • Cihan Ay

    Medical University of Vienna

    3 shared publications
  • Benedikt Weber

    Department of Dermatology, Medical University of Vienna, Vienna, Austria

    2 shared publications
  • Ingrid Pabinger

    Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

    2 shared publications
  • Oliver Schlager

    Division of Angiology, Department of Medicine II, Medical University of Vienna, Vienna, Austria https://twitter.com/SchlagerOliver

    2 shared publications
  • Stephan Nopp

    Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

    2 shared publications

Latest Publications

  • Open Access

    Galectin-9 drives thrombo-inflammatory circuits initiating venous thrombosis

    by Akhil A. Konkoth, Adel Abo Mansour, Katharine Whitworth, Ivan Budnik, Daniel Steiner, Cihan Ay, Danielle Lezama, Helen M. McGettrick, Dean Kavanagh, Francesco Maione, et al.

    Background: Venous thromboembolism is increasingly recognized as a thrombo-inflammatory disease, yet the pathways linking inflammation to venous thrombus initiation remain incompletely defined. Galectin-9 (Gal-9), a β-galactoside-binding lectin elevated in inflammatory disorders, has no defined role in venous thrombosis. Methods: Using plasma from patients with deep vein thrombosis (DVT), Gal-9-deficient mice, an inferior vena cava stenosis model, intravital microscopy, microfluidics, and ex vivo platelet and neutrophil assays, we assessed the functional contribution of Gal-9 to venous thrombosis. Results: Plasma Gal-9 was elevated in DVT patients, correlated with D-dimer at presentation, and declined over 3-month follow-up. Gal-9 deletion did not alter hemostasis but markedly impaired thrombus initiation, with reduced platelet and neutrophil recruitment to the vessel wall and reduced intra-thrombus neutrophil extracellular trap (NET) formation. TNF-α/IFN-γ-stimulated endothelial cells upregulated Gal-9 and promoted platelet adhesion and fibrin(ogen) deposition, which Gal-9 neutralization partially reversed. Under venous shear, immobilized recombinant Gal-9 potentiated platelet activation and thrombus formation, particularly alongside collagen, whereas Gal-9 inhibition suppressed these responses. Gal-9-activated platelets promoted NETosis and shifted thrombus composition toward a NET-rich inflammatory phenotype. Conclusions: Gal-9 is a previously unrecognized driver of venous thrombo-inflammation, linking vascular inflammation to platelet activation, NET formation, and thrombosis. Genetic deletion attenuated these responses in vivo, and antibody-mediated Gal-9 neutralization suppressed platelet activation and thrombus formation in vitro, identifying the Gal-9 glycan-binding pathway as a therapeutic target that disrupts thrombosis without impairing hemostasis.

  • Open Access

    Walking capacity and venous claudication after deep vein thrombosis: prospective follow-up, risk factors, and quality of life

    by Daniel Steiner, Stephan Nopp, Timothy Hoberstorfer, Ingrid Pabinger, Eva Dassler, Moritz Staudacher, Markus Müller, Sabine Steiner, Benedikt Weber, Philip Kienzl, et al.

  • Top Cited Papers

    Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study

    by Cornelia Englisch, Florian Moik, Daniel Steiner, Angelika M. Starzer, Anna S. Berghoff, Matthias Preusser, Ingrid Pabinger, Cihan Ay

    Hemostatic imbalances are frequent in patients with cancer. Although cancer-associated thrombotic complications have been well characterized, data on bleeding events in patients with cancer are sparse. Therefore, we aimed to investigate the incidence, risk factors, and impact on prognosis of bleeding events in patients with cancer initiating systemic anticancer therapies in a prospective cohort study, the Vienna Cancer, Thrombosis, and Bleeding Study. The primary study outcome was defined as clinically relevant bleeding (CRB), comprising major bleeding (MB) and clinically relevant nonmajor bleeding. In total, 791 patients (48% female), with median age of 63 years (interquartile range [IQR], 54-70), with various cancer types, 65.5% stage IV, were included. Over a median follow-up of 19 months (IQR, 8.7-24.0), we observed 194 CRB events in 139 (17.6%) patients, of which 42 (30.0%) were tumor related, 64 (46.0%) gastrointestinal, and 7 (5.0%) intracerebral. The 12-month cumulative incidence of first CRB and MB was 16.6% (95% confidence interval [CI], 13.7-19.6) and 9.1% (95% CI, 6.8-11.3), respectively, in the whole cohort, and 14.4% (95% CI, 11.2-17.5) and 7.0% (95% CI, 4.7-9.2), respectively, in those without anticoagulation. Patients with head and neck cancer had the highest risk of CRB. Lower baseline hemoglobin and albumin were associated with bleeding in patients without anticoagulation. Seven (5.0%) bleeding events were fatal, of which 6 occurred in patients without anticoagulation. Patients with CRB were at an increased risk of all-cause mortality (multivariable transition hazard ratio, 5.80; 95% CI, 4.53-7.43). In patients with cancer, bleeding events represent a frequent complication and are associated with increased mortality.


  • Open Access

    Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world analysis

    by Leyla Ay, Daniel Steiner, Hannah Fabikan, Oliver Illini, Dagmar Krenbek, Thomas Klikovits, Michal Benej, Klaus Kirchbacher, Stefan Watzka, Arschang Valipour, et al.


  • Open Access

    Functional limitations 3 and 12 months after venous thromboembolism: a cohort study

    by Daniel Steiner, Stephan Nopp, Georg Heinze, Daniel Kraemmer, Oliver Schlager, Stefano Barco, Frederikus A. Klok, Ingrid Pabinger, Benedikt Weber, Cihan Ay


  • Risk of Depression after Venous Thromboembolism in Patients with Hematological Cancer: A Population-Based Cohort Study

    by Daniel Steiner, Erzsébet Horváth-Puhó, Helle Jørgensen, Kristina Laugesen, Cihan Ay, Henrik Toft Sørensen

    Background Venous thromboembolism (VTE) may complicate the clinical course of cancer patients and add to their psychological burden. Objectives We aimed to investigate the association between VTE and risk of subsequent depression in patients with hematological cancer. Patients and Methods We conducted a population-based cohort study using Danish national health registries. Between 1995 and 2020, we identified 1,190 patients with hematological cancer and incident VTE diagnosed within 6 months before to 1 year after cancer diagnosis. A comparison cohort of patients with hematological cancer without VTE (n = 5,325) was matched by sex, year of birth, cancer type, and year of cancer diagnosis. Patients were followed until diagnosis of depression, emigration, death, study end (2021), or for a maximum of 3 years. Depression was defined as hospital discharge diagnosis of depression or ≥1 prescription for antidepressants. Absolute risks of depression were computed with cumulative incidence functions, treating death as competing event. Hazard ratios (HRs) with 95% confidence intervals (CIs) were computed using Cox proportional hazards regression models, adjusting for comorbidities. Results Depression was observed in 158 hematological cancer patients with and 585 without VTE. The 3-year absolute risks of depression were 13.3% (95% CI: 11.5–15.3%) in the VTE cancer cohort and 11.1% (95% CI: 10.3–12.0%) in the comparison cancer cohort, corresponding to a risk difference of 2.2% (95% CI: -1.8–6.5%). VTE was associated with an increased relative risk of depression (adjusted HR: 1.56, 95% CI: 1.28–1.90). Conclusion VTE was associated with an elevated risk of subsequent depression in patients with hematological cancer.


  • Open Access

    Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity

    by Christoph Suppan, Florian Posch, Hannah Deborah Mueller, Nina Mischitz, Daniel Steiner, Eva Valentina Klocker, Lisa Setaffy, Ute Bargfrieder, Robert Hammer, Hubert Hauser, et al.

    Background: The prognostic performance of the residual cancer burden (RCB) score is a promising tool for breast cancer patients undergoing neoadjuvant therapy. We independently evaluated the prognostic value of RCB scores in an extended validation cohort. Additionally, we analyzed the association between chemotherapy dose reduction and RCB scores. Methods: In this extended validation study, 367 breast cancer patients with available RCB scores were followed up for recurrence-free survival (RFS), distant disease-free survival (DDFS), and overall survival (OS). We also computed standardized cumulative doses of anthracyclines and taxanes (A/Ts) to investigate a potential interaction between neoadjuvant chemotherapy dose reduction and RCB scores. Results: Higher RCB scores were consistently associated with adverse clinical outcomes across different molecular subtypes (HR for RFS = 1.60, 95% CI 1.33–1.93, p < 0.0001; HR for DDFS = 1.70, 95% CI 1.39–2.05, p < 0.0001; HR for OS = 1.67, 95% CI 1.34–2.08, p < 0.0001). The adverse impact prevailed throughout 5 years of follow-up, with a peak for relapse risk between 1–2 years after surgery. Clinical outcomes of patients with RCB class 1 did not differ substantially at 5 years compared to RCB class 0. A total of 180 patients (49.1%) underwent dose reduction of neoadjuvant A/T chemotherapy. We observed a statistically significant interaction between dose reduction and higher RCB scores (interaction p-value = 0.042). Conclusion: Our results confirm RCB score as a prognostic marker for RFS, DDFS, and OS independent of the molecular subtype. Importantly, we show that lower doses of cumulative neoadjuvant A/T were associated with higher RCB scores in patients who required a dose reduction.


  • Open Access

    Rhabdomyosarcoma and pleomorphic sarcoma in the same location

    by Daniel Steiner, Maria Anna Smolle, Iva Brcic, Andreas Leithner

    Summary: Soft tissue sarcomas (STS) represent a small group of adult solid malignancies, with risk factors such as environmental factors, genetic predisposition, and prior radiotherapy. In STS patients with a novel swelling, differential diagnoses include recurrence, second primary cancer, metastasis from unknown primary cancer, and radiation-associated STS, the latter usually occurring approximately 10 years after radiotherapy. We present the case of a 64-year-old male patient with pleomorphic rhabdomyosarcoma, who underwent resection and radiotherapy. The patient presented again 5 years later with painful swelling in the area of the prior sarcoma, raising suspicion of recurrence. Resection was performed and a diagnosis of pleomorphic sarcoma (not otherwise specified [NOS]) was made. The patient was treated with radiotherapy and remained sarcoma-free for the following 7 years. A molecular analysis of both neoplasms, using RNA next-generation sequencing, did not detect any specific fusions. Due to the lack of rhabdomyoblastic differentiation in the second sarcoma and the low likelihood of a second primary in the same previously irradiated location, the diagnosis of a radiation-associated STS was suggested. This short report illustrates the difficult diagnostic work-up of a presumably radiation-associated STS, as these neoplasms lack characteristic morphological and immunohistochemical features. In our case, the suggested diagnosis may have pointed against another course of radiotherapy in an already irradiation-harmed region. Therefore, a relatively low latency period between surgery, radiotherapy, and diagnosis of another STS should not automatically point towards recurrence and may prompt further in-depth investigation.